No Data
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Its core products are mainly suitable for the treatment of chronic diseases in the elderly.
On January 9, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform that the company's core products are mostly suitable for the treatment of chronic diseases in the elderly, such as Compound Thrombus Capsule, Cerebral Thrombus Capsule, and Compound Danshen Tablets, among others. The company has partnered with major chain pharmacies to launch the "Caring for the Silver Age•Health for All" project, forming a product package for chronic diseases that combines Compound Thrombus Capsule, Cerebral Thrombus Capsule, and other featured products. The aim is to provide services including testing, patient education, and medication guidance for common diseases in the elderly, empowering county-level chain pharmacies to improve the service system for the elderly with higher quality products and more professional support.
The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.
① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.
Individual Investors Among Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Largest Stockholders and Were Hit After Last Week's 3.6% Price Drop
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The phase II clinical trial of the Innovative Drug RAY1225 injection for lowering blood sugar has obtained top-line analysis data results from the sub-study.
On December 30, Glonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative peptide drug, RAY1225 injection, which is used in the Phase II clinical trial for type 2 diabetes patients, and has recently obtained the top-line analysis data from the sub-study. Preliminary results indicate that RAY1225 injection has shown positive efficacy and good safety in adult participants with type 2 diabetes in China, with the trial results being ideal and achieving the expected objectives.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): A subsidiary has obtained a patent certificate in Europe.
On December 12, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), received a patent certificate issued by the European Patent Office. The invention is titled: TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME (tyrosine kinase inhibitor and pharmaceutical composition containing the same). This patent is for Zhongsheng Ruichuang.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): the existing product Fumaric Acid Chlorpheniramine Maleate Oral Solution is a pediatric dosage form.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on November 14th that, according to the "Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (2020)", oral antihistamines are recommended for the auxiliary treatment of atopic dermatitis itching. The company's existing product, Chlorpheniramine Malate Oral Solution, is a pediatric formulation. The company is also actively focusing on the research and development, production, and sales of pediatric medications.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
